BMO Lifts AbbVie Inc. (ABBV) Price Target to $240 After Rinvoq Litigation Win

Core Viewpoint - AbbVie Inc. (NYSE:ABBV) is positioned as a high-growth mega-cap stock with a price target increase to $240 from $215, indicating a potential upside of nearly 10% following the resolution of litigation with generic drugmakers, allowing early market entry of generic Rinvoq [1] Group 1: Financial Performance and Market Position - AbbVie Inc. is expected to surpass market expectations due to the delayed entry of generic competition until 2037, four years after the 2033 expiration of the composition of matter patent [2] - The company has delivered a year-to-date return that outperforms the market by 14.31% [2] Group 2: Strategic Developments - AbbVie is expanding its neuroscience portfolio through the acquisition of Gilgamesh's bretisilocin and has improved overall guidance, reinforcing its position as a leading stock for the upcoming years [3] - The company is recognized for its consistent dividend track record, contributing to its reputation as a reliable investment [3] Group 3: Company Overview - AbbVie Inc. is a research-focused biopharmaceutical company based in Illinois, providing medicines and therapies internationally, with core offerings including Humira, Skyrizi, Rinvoq, Imbruvica, and Epkinly [4]